TENX stock forecast, quote, news & analysis
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension... Show more
Tenax Therapeutics (TENX) Stock Analysis: The LEVEL Trial Miss and the Road to a Second Readout
Key Takeaways
- Tenax Therapeutics (TENX) is a development-stage biopharmaceutical company advancing TNX-103 (levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
- Shares traded near $1.72, roughly 5% lower over the trailing month, following a much larger multi-month decline from a 52-week high of $19.40.
- The Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, although a pre-specified analysis showed a stronger signal in sicker patients.
- Guggenheim downgraded the stock to Neutral from Buy, citing clinical and regulatory uncertainty.
- Tenax reported $97.6 million in cash and cash equivalents at the end of 2025 and has guided a runway into 2027.
- The company is now advancing LEVEL-2, a second global Phase 3 study, with enrollment completion targeted for the end of 2027.
- For deeper detail, explore Tenax's Price Targets, Earnings, and Forecast pages.
- Discover Trending AI Robots to see how automated strategies are positioned across the market.
Current Market Snapshot
Tenax Therapeutics trades as a small-cap biotech in a period of elevated volatility following a pivotal clinical readout. After peaking at a 52-week high of $19.40, the stock retreated sharply and now changes hands near $1.72, not far above its 52-week low of $1.31. The trailing one-month move is comparatively modest at roughly 5% lower, but that stability masks a steep earlier drawdown driven by trial results rather than broad-market weakness.
Sentiment around TENX has cooled considerably. The equity remains a binary, catalyst-driven story tied almost entirely to the clinical development of its lead cardiopulmonary asset. With no marketed products generating revenue, the company's valuation is underpinned by its cash position and the future prospects of its pipeline rather than current fundamentals.
Tenax Therapeutics (TENX) Business Overview and Competitive Position
Tenax Therapeutics, headquartered in Chapel Hill, North Carolina, is a Phase 3, development-stage pharmaceutical company focused on novel cardiopulmonary therapies. The company was founded in 1967 and formerly operated as Oxygen Biotherapeutics before adopting its current name in 2014.
Its lead candidate, TNX-103, is an oral formulation of levosimendan being developed for PH-HFpEF, a condition for which there are no approved treatment options. The company is pursuing a registrational pathway through its LEVEL and LEVEL-2 Phase 3 programs. The opportunity is significant: PH-HFpEF represents a large, underserved patient population with a high unmet medical need, which is why the stock has historically attracted investor attention despite its development-stage status.
Recent Developments Driving TENX
The dominant event shaping TENX has been the readout of the Phase 3 LEVEL trial of TNX-103. The study did not meet its primary endpoint on the overall PH-HFpEF population, triggering a steep sell-off and a reassessment of the investment case. However, a pre-specified analysis indicated a more meaningful effect in sicker patients, with those below the trial's median baseline six-minute walk distance showing a roughly 26.3-meter improvement versus placebo, a result reported as statistically significant.
These findings were presented in a late-breaking session at the ESC Congress 2026. In response, Guggenheim downgraded the stock to Neutral from Buy, citing clinical and regulatory uncertainty. The company has maintained its development path, advancing LEVEL-2, a second global registrational Phase 3 study, along with an open-label extension for patients completing the pivotal trials.
Financially, Tenax reported $97.6 million in cash and cash equivalents at the end of 2025, with management indicating the balance is expected to fund operations into 2027. The company also received a U.S. patent notice of allowance expanding protection for subcutaneous levosimendan formulations across a range of cardiovascular indications.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's top-performing automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the most relevant and best-performing bots are surfaced in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing traders to evaluate approaches that suit different objectives and risk profiles. For investors tracking volatile, catalyst-driven names like Tenax Therapeutics, the section provides a view into how quantitative systems are navigating changing market conditions.
2026 Outlook and What Investors Should Watch
Looking ahead, the central focus remains the clinical trajectory of TNX-103. Investors will monitor enrollment and execution of the LEVEL-2 study, which the company expects to complete enrollment by the end of 2027. Any updates on the regulatory pathway, additional data from the LEVEL program's pre-specified analyses, and feedback from health authorities will be key catalysts.
Quarterly earnings and cash-burn disclosures also matter for a development-stage company with no commercial revenue. Management's ability to preserve its runway into 2027 while funding two global Phase 3 trials will be closely scrutinized. Broader factors such as biotech financing conditions, sector rotation, and analyst sentiment will continue to influence price action. As with all early-stage biopharmaceutical investments, the outcome of ongoing trials remains the primary driver of long-term value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TENX's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for TENX moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 30 of the 35 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TENX as a result. In 74 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +14.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 190 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.590) is normal, around the industry mean (3.162). P/E Ratio (-1.209) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapeutic products
Industry Biotechnology